Fennec Pharmaceuticals

Yahoo Finance • last month

Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss

– Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK® when Compared with Historically Reported Rates of Hearing Loss in Patients Receiving Cis... Full story

Yahoo Finance • 2 months ago

Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will participate in a fireside ch... Full story

Yahoo Finance • 2 months ago

Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption

RESEARCH TRIANGLE PARK, N.C., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced it has repurchased and redeemed all of... Full story

Yahoo Finance • 2 months ago

Fennec Pharmaceuticals Announces Closing of Offering of Common Shares

RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the closing of its underwritten register... Full story

Yahoo Finance • 2 months ago

Fennec Pharmaceuticals plans share offering in Canada to raise up to $5 million

* Fennec Pharmaceuticals (FENC [https://seekingalpha.com/symbol/FENC]) intends [https://seekingalpha.com/pr/20307705-fennec-pharmaceuticals-announces-private-offering-of-common-shares-in-canada]to engage in a non-brokered offering of it... Full story

Yahoo Finance • 2 months ago

Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that it intends to engage in a non-broke... Full story

Yahoo Finance • 2 months ago

Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the pricing of its underwritten register... Full story

Yahoo Finance • 2 months ago

Fennec Pharmaceuticals announces proposed offering of common shares

* Fennec Pharmaceuticals (NASDAQ:FENC [https://seekingalpha.com/symbol/FENC]) stated [https://seekingalpha.com/pr/20307363-fennec-pharmaceuticals-announces-proposed-offering-of-common-shares] on Thursday that it would sell its common sha... Full story

Yahoo Finance • 2 months ago

Fennec Pharmaceuticals Announces Proposed Offering of Common Shares

Yahoo Finance • 2 months ago

Fennec Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

~ Q3 2025 Total Net Product Sales of $12.5 Million, 79% Year Over Year Growth ~ ~ Q3 2025 Positive Cash Flow from Operations, Cash Position Grew to $22 Million ~ ~ Japan Clinical Trial (STS-J01) Preliminary Results Expected in Q4 2025 ~... Full story

Yahoo Finance • 5 months ago

Fennec Q2 Sales Jump 33 Percent

Fennec Pharmaceuticals (NASDAQ:FENC) reported second quarter 2025 earnings on August 14, 2025, GAAP net product sales of $9.7 million, up 33% year over year compared to the same period last year and 10% sequentially, matching a quarterly r... Full story

Yahoo Finance • 5 months ago

Fennec Pharmaceuticals Inc (NASDAQ:FENC) Reports Mixed Q2 2025 Earnings with Revenue Slight Miss and Wider-Than-Expected Loss

Fennec Pharmaceuticals Inc (NASDAQ:FENC [https://www.chartmill.com/stock/quote/FENC/profile]) reported its second-quarter 2025 financial results, revealing mixed performance relative to analyst expectations. The company posted total net re... Full story

Yahoo Finance • 5 months ago

Fennec Pharmaceuticals GAAP EPS of -$0.11 misses by $0.08, revenue of $9.65M beats by $0.09M

* Fennec Pharmaceuticals press release [https://seekingalpha.com/pr/20200624-fennec-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides-business] (NASDAQ:FENC [https://seekingalpha.com/symbol/FENC]): Q2 GAAP EPS of... Full story

Yahoo Finance • 5 months ago

Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025

RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2... Full story

Yahoo Finance • 7 months ago

Fennec Announces Results of Annual Meeting

RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 25, 2025 were elect... Full story

Yahoo Finance • 4 years ago

DEADLINE ALERT for ASTR, FENC, and GWGH: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, April 11, 2022 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the... Full story

Yahoo Finance • 4 years ago

Fennec Pharmaceuticals, Inc. Investors: Reach out to the Portnoy Law Firm prior to the April 11, 2022 Deadline

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, April 08, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”) (NASDAQ: FENC... Full story

Yahoo Finance • 4 years ago

DEADLINE ALERT for TLS, ASTR, FENC, AFIB: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

BENSALEM, Pa., April 07, 2022 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the... Full story

Mentioned:

Yahoo Finance • 4 years ago

FENC FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Fennec Pharmaceuticals Inc. Investors to Secure Counsel Before Important Monday Deadline in Securities Class Action – FENC

NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between May 28, 2021 and November 26, 2021, inclusiv... Full story

Yahoo Finance • 4 years ago

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fennec, Astra, Acutus, and Pulse and Encourages Investors to Contact the Firm

NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Fennec Pharmaceuticals,... Full story

Mentioned:

PLSE